

From: Thompson, Edward
Sent: Thursday, April 30, 2015 7:26 AM
To: 'Kevin Darryl (KD) White (Kevin.White@cslbehring.com)'
Cc: Monica.Richardson@cslbehring.com
Subject: Information Request for BL 125582/0

Contacts: Kevin Darryl (KD) White - CSL Behring

Dear Mr. White:

We are reviewing your December 5, 2014 biologics license application (BLA) for Coagulation Factor IX (Recombinant), Albumin Fusion Protein. We determined that the following information is necessary to continue our review:

1. Please clarify what the events in Protocol 3001, Complete Study Report (CSR), Table 14.2.8.7 page 1 (p. 655) represent. In particular describe the relationship of Table 14.2.8.7 spontaneous bleeding events - any (total = 147) to the spontaneous bleeding events reported in Table 14.2.8.3 (Bleeding Episodes Requiring Treatment by Event (Efficacy Population)) p.5 (Spontaneous Bleeding Episodes) (total = 204) and Listing 16.2.6.3 (total = 204).
2. Please provide a schedule for harmonizing the draft label and the investigator's brochure with the additional data reported Apr 3, 2015 for studies 3001, 3002, and 3003. The discrepancy in the number of surgeries in these documents brought this to attention, but the revisions should be comprehensive.
3. Study 3001 CSR Section 12.7.2.5, Markers for coagulation activation states, "No values outside of normal range were observed in the study", but Listing 16.2.8.4, Laboratory Results Activation of Coagulation Tests, provides no normal values to allow interpretation of these results. Please provide the normal values that were used for the tests, prothrombin fragment 1+2, thrombin-antithrombin and D-dimer, and interpretation of results that are outside of the reported normal range.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by May 11, 2015 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is December 5, 2015.

Please send an acknowledgement for receipt of this request.

If you have any questions, please contact me at (240) 402-8443.

Sincerely,

Edward Thompson
Regulatory Project Manager
FDA/CBER/OBRR/PPMS